Hypersensitivity to the active ingredients, to any excipients or to residues (e.g. eggs or chicken protein, such as egg albumin). Known hypersensitivity to any of the following substances that may be present as residues: kanamycin and neomycin sulphate, formaldehyde, cetyltrimethylammonium bromide (CTAB), barium sulphate and polysorbate 80. Previous anaphylactic reaction to influenza vaccination. Immunisation should be postponed in patients with febrile conditions or acute infection.
Adverse reactions reported during clinical studies the following side effects were observed during clinical studies at the following frequencies: very common (>=1/10), common (>=1/100, =1/1.000, =1/10.000, =1/100, =1/100, =1/100, =1/100,
Prophylaxis of influenza, especially in those who are at greater risk of associated complications. Agrippal S1 is indicated in adults and children from 6 months of age. The use of Agrippal S1 should be carried out on the basis of official recommendations
Adults: 0.5 ml. Paediatric population. Children 36 months of age or older: 0.5 ml. Children aged 6 to 35 months: clinical data are limited. Dosages of 0.25 ml or 0.5 ml can be used. The dose administered should comply with the existing national recommendation. Children who have not been previously vaccinated should be given a second dose after an interval of at least 4 weeks. Children under 6 months of age: safety and efficacy in children under 6 months of age have not been established. No data available. Method of administration: immunisation should be done by intramuscular or deep subcutaneous injection
